Light at Night Tied to Higher Risk for Mental Health Disorders
Medically reviewed by Drugs.com.
By Lori Solomon HealthDay Reporter
TUESDAY, Nov. 28, 2023 -- Avoiding light at night and seeking natural light during the day may be an effective way to improve mental health, according to a study published online Oct. 9 in Nature Mental Health.
Angus C. Burns, Ph.D., from Monash University in Melbourne, Australia, and colleagues examined associations between daytime and nighttime light exposure with the risk for psychiatric disorders and self-harm. The analysis included 86,772 adults (57 percent women).
The researchers found that greater nighttime light exposure was associated with an increased risk for major depressive disorder, generalized anxiety disorder, posttraumatic stress disorder (PTSD), psychosis, bipolar disorder, and self-harm behavior. Greater daytime light exposure was associated with a reduced risk for major depressive disorder, PTSD, psychosis, and self-harm behavior, independent of nighttime light exposure. When adjusting for sociodemographics, photoperiod, physical activity, sleep quality, and cardiometabolic health, the findings persisted.
"Avoiding light at night and seeking light during the day may be a simple and effective, nonpharmacological means of broadly improving mental health," the authors write.
Several authors disclosed ties to industry.
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.
Source: HealthDay
Posted : 2023-11-29 00:32
Read more
- More Activity, Less Risk: Tell Your MD How Much You Move
- Genentech’s Phase IIb Study of Prasinezumab Missed Primary Endpoint, but Suggests Possible Benefit in Early-Stage Parkinson’s Disease
- Denture Use Tied to Better Cognitive Health in Older Adults With Partial Tooth Loss
- Data Suggests TNF Inhibitors Help Prevent Serious Complications in Children with Crohn's Disease
- uniQure Announces Alignment with FDA on Key Elements of Accelerated Approval Pathway for AMT-130 in Huntington’s Disease
- U.S. Seeing Sharp Rise in Norovirus Cases This December
Disclaimer
Every effort has been made to ensure that the information provided by Drugslib.com is accurate, up-to-date, and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. Drugslib.com information has been compiled for use by healthcare practitioners and consumers in the United States and therefore Drugslib.com does not warrant that uses outside of the United States are appropriate, unless specifically indicated otherwise. Drugslib.com's drug information does not endorse drugs, diagnose patients or recommend therapy. Drugslib.com's drug information is an informational resource designed to assist licensed healthcare practitioners in caring for their patients and/or to serve consumers viewing this service as a supplement to, and not a substitute for, the expertise, skill, knowledge and judgment of healthcare practitioners.
The absence of a warning for a given drug or drug combination in no way should be construed to indicate that the drug or drug combination is safe, effective or appropriate for any given patient. Drugslib.com does not assume any responsibility for any aspect of healthcare administered with the aid of information Drugslib.com provides. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the drugs you are taking, check with your doctor, nurse or pharmacist.
Popular Keywords
- metformin obat apa
- alahan panjang
- glimepiride obat apa
- takikardia adalah
- erau ernie
- pradiabetes
- besar88
- atrofi adalah
- kutu anjing
- trakeostomi
- mayzent pi
- enbrel auto injector not working
- enbrel interactions
- lenvima life expectancy
- leqvio pi
- what is lenvima
- lenvima pi
- empagliflozin-linagliptin
- encourage foundation for enbrel
- qulipta drug interactions